Endotoxin contamination from gram-negative bacteria can cause severe pyrogenic reactions even after sterilization. LAL methods (gel-clot, turbidimetric, chromogenic) are standardized in USP <85> and ISO 10993-1 references. Devices contacting blood, the cardiovascular system or cerebrospinal fluid have limits, commonly 20 EU per device, or 2.15 EU per device for intrathecal contact, as described in FDA guidance and ANSI/AAMI ST72. Recombinant Factor C tests are a newer alternative to LAL that avoids horseshoe crab blood. Testing usually occurs on lot samples before release.

Why it matters

Required for blood-contacting and implantable devices; endotoxin failures often trace back to water systems or component handling, not the sterilization step itself.

Common pitfalls

•Assuming sterilization eliminates endotoxins, which are heat-stable and require specific depyrogenation processes.
•Failing to routinely monitor water systems for endotoxin levels, a common source of contamination.
•Not validating the LAL test method for each specific device or material, which can lead to inhibition or enhancement.
•Using an LAL test method not suitable for the product's matrix, yielding inaccurate results.
•Overlooking the endotoxin limits specified in relevant pharmacopeias or standards for the device type.

Sources

USP <85> · USP
GHTF/IMDRF Process Validation Guidance · IMDRF/GHTF
FDA - Device Manufacturing · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.